Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.